Viracta Therapeutics Inc Stock
Viracta Therapeutics Inc Stock price
Key metrics
| Market capitalization | $8.69m |
| Enterprise Value | $2.95m |
| P/E (TTM) P/E ratio | negative |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-49.50m |
| Cash position | $30.01m |
| EPS (TTM) EPS | $-1.16 |
| P/E forward | negative |
Is Viracta Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
Viracta Therapeutics Inc Stock Analysis
Analyst Opinions
3 Analysts have issued a Viracta Therapeutics Inc forecast:
Analyst Opinions
3 Analysts have issued a Viracta Therapeutics Inc forecast:
Financial data from Viracta Therapeutics Inc
| Jun '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.46 -0.46 |
35%
35%
|
|
| EBITDA | -49 -49 |
9%
9%
|
EBIT (Operating Income) EBIT | -50 -50 |
9%
9%
|
| Net Profit | -45 -45 |
14%
14%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Viracta Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Viracta Therapeutics Inc Stock News
Company Profile
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
| Head office | United States |
| CEO | Mark Rothera |
| Employees | 40 |
| Founded | 1998 |
| Website | www.viracta.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
